CAR T Cells Show Efficacy for Aggressive Large B Cell Lymphoma

CAR T cells continue to show efficacy for the treatment of relapsed and/or refractory large B cell lymphoma, according to an update in Nature Reviews Clinical Oncology. Data from the ZUMA-1 and JULIET trials demonstrated that chimeric antigen receptor (CAR) T cells targeting the B cell surface receptor CD19 can induce durable disease remission in 30-40% of patients with cancer that relapsed and/or ceased responding to first-line therapies. CAR T cells are genetically engineered to express a unique and modifiable cell surface receptor that enables the direct identification and destruction of cancerous cells.

While treatment with CAR T cells has been associated with severe and potentially life-threatening side effects, these trials demonstrated no unexpected toxicities at two-year follow-up. Future studies will continue to increase the safety, efficacy, and accessibility of this therapeutic option over the next decade.

Maloney DG. (2019) Anti-CD19 CAR T cell therapy for lymphoma — off to the races! Nature Reviews Clinical Oncology.

Learn more about the latest cancer research and therapies relevant to the field of immunology.